Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenishaw Regulatory News (RSW)

Share Price Information for Renishaw (RSW)

Share Price is delayed by 15 minutes
Get Live Data
5,370.00    -85.00 (-1.56%)
Bid:
5,365.00
Ask:
5,375.00
Spread: 10.00 (0.186%)
Market Cap: £3.91b
RSW Live PriceLast checked at - London Stock Exchange

Intraday Renishaw Share Chart

Trading Statement

24 Oct 2024 07:00

RNS Number : 3723J
Renishaw PLC
24 October 2024
 

Renishaw plc

Trading update

24 October 2024

 

 

Solid revenue and profit growth in mixed trading conditions

Renishaw plc, the global provider of manufacturing technologies, analytical instruments and medical devices, publishes this trading update for the three months ended 30 September 2024. It contains unaudited information that covers the first quarter of the financial year.

 

 

Trading activity

 

 

3 months to 30 September 2024

3 months to 30 September 2023

Change

 

 

 

 

Manufacturing technologies

£167.5m

£156.8m

+7%

Analytical instruments and medical devices

£6.4m

£7.7m

-16%

Total revenue

£173.9m

£164.5m

+6%

Total revenue at constant exchange rates1

£171.3m

£165.0m

+4%

 

 

 

Adjusted profit before tax2

£34.0m

£28.0m

+22%

Statutory profit before tax

£34.0m

£28.0m

+22%

 

 

Revenue was £173.9m, representing a 6% increase compared to the corresponding period last year at actual exchange rates, and a 4% increase at constant currency1. The Americas and EMEA regions saw increased demand compared to Q1 FY2024, whilst APAC was lower compared to a strong period last year, which was boosted by orders from the consumer electronics sector. 

 

In our Manufacturing technologies business, revenue in the period was 7% higher than the prior year at £167.5m. Sales of position encoders to the semiconductor manufacturing sector saw strong growth compared to a subdued prior year comparator. Our Additive Manufacturing products also grew strongly, reflecting the good order book carried into FY2025. Meanwhile, demand for Industrial Metrology products was lower than last year, primarily due to the strong prior period sales to consumer electronics manufacturers in APAC.

 

Revenue for our Analytical instruments and medical devices business was £6.4m, a decrease of 16% compared with £7.7m last year, primarily from phasing for our Spectroscopy products.

 

Adjusted and Statutory profit before tax2 for the first quarter of FY2025 both amounted to £34.0m (FY2024: £28.0m).

 

 

Financial position

 

The Group's balance sheet remains strong with net cash and cash equivalents and bank deposit balances of £276.1m on 30 September 2024 (30 June 2024: £217.8m).

 

 

Outlook

 

The first quarter of FY2025 has seen solid revenue and profit growth in mixed trading conditions, with subdued demand in some markets, offset by good growth elsewhere. Whilst Q1 sales of our encoder products to the semiconductor manufacturing sector have been stronger than last year, we remain cautious about demand from this market in the remainder of FY2025. 

 

We continue to pursue a range of growth opportunities and anticipate solid overall revenue growth this year in line with the Board's expectations. Alongside this we also remain focused on the careful management of costs and delivery of productivity improvements, which together will help drive progress towards our margin objectives.

The results for the half year ending 31 December 2024 will be released on 13 February 2025.

 

Will Lee

Allen Roberts

 

Chief Executive

Group Finance Director

 

 

24 October 2024

 

 

Renishaw plc

Registered office

New Mills, Wotton-under-Edge, Gloucestershire, GL12 8JR

Registered number

01106260

Telephone number

+44 (0) 1453 524524

Website

www.renishaw.com

 

 

 

Notes

 

1. Revenue at constant exchange rates is defined as revenue recalculated using the same rates that were applicable to the previous year and excluding forward contract gains and losses.

2. There are no adjustments made between statutory and adjusted profit before tax.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAKEDALELFFA
Date   Source Headline
16th May 20239:45 amRNSAGM Voting Results Update Statement
9th May 20233:39 pmRNSNotice of Investor Day
28th Apr 20237:00 amRNSTrading Statement
2nd Feb 20237:00 amRNSHalf-year Report
24th Jan 20233:11 pmRNSNotice of Half-year Results
30th Nov 20224:38 pmRNSResult of AGM
31st Oct 20221:00 pmRNSNotice of AGM
28th Oct 20229:15 amRNSDirector/PDMR Shareholding
27th Oct 20227:00 amRNSTrading Statement
30th Sep 20227:00 amRNSAnnual Financial Report
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
15th Sep 20227:00 amRNSFinal Results
6th Sep 20221:00 pmRNSNotice of Results
1st Jul 202212:31 pmRNSDirector Declaration
16th May 20225:56 pmRNSDirector/PDMR Shareholding
16th May 20227:00 amRNSAGM Voting Results Update Statement
10th May 20227:00 amRNSTrading Statement
12th Apr 202211:44 amRNSNotice of Investor Day
12th Apr 202210:58 amRNSDirector/PDMR Shareholding
31st Mar 20221:00 pmRNSDirectorate Change
18th Mar 20222:08 pmRNSHolding(s) in Company
14th Mar 20225:58 pmRNSDirector/PDMR Shareholding
1st Mar 20224:23 pmRNSDirectorate Change
3rd Feb 20227:00 amRNSHalf-year Report
17th Jan 20221:00 pmRNSNotice of Half-year Results
20th Dec 20214:05 pmRNSDirectorate Change
24th Nov 20213:57 pmRNSResult of AGM
29th Oct 20218:00 amRNSDirector/PDMR Shareholding
29th Oct 20217:00 amRNSAnnual Financial Report
21st Oct 202111:50 amRNSFinal Results Replacement
21st Oct 20217:00 amRNSFinal Results
21st Oct 20217:00 amRNSTrading Statement
27th Sep 202110:52 amRNSFinal Results Revised Date and Trading Update
17th Sep 202110:35 amRNSNotice of Results
31st Aug 202112:31 pmRNSHolding(s) in Company
3rd Aug 20213:05 pmRNSDirector/PDMR Shareholding
8th Jul 20213:20 pmRNSForm 8.3 - Renishaw plc
8th Jul 20217:00 amRNSForm 8.3
7th Jul 20213:20 pmRNSForm 8.3 - Renishaw plc
7th Jul 20213:13 pmRNSForm 8.3 - Renishaw plc
7th Jul 20212:26 pmEQSForm 8.3 - The Vanguard Group, Inc.: Renishaw plc
7th Jul 202111:48 amRNSForm 8.5 (EPT/NON-RI) - Renishaw plc
7th Jul 202111:14 amRNSForm 8.5 (EPT/RI) - Renishaw Plc
7th Jul 20217:00 amRNSUpdate on Formal Sale Process & Current Trading
6th Jul 20213:20 pmRNSForm 8.3 - Renishaw plc
6th Jul 20213:09 pmRNSForm 8.3 - Renishaw plc
6th Jul 20212:38 pmRNSForm 8.3 - Renishaw Plc
6th Jul 20212:13 pmRNSForm 8.3 - Renishaw Plc
6th Jul 20212:05 pmEQSForm 8.3 - The Vanguard Group, Inc.: Renishaw plc
6th Jul 202111:36 amRNSForm 8.5 (EPT/RI) - Renishaw Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.